Int J Stomatol

Int J Stomatol ›› 2024, Vol. 51 ›› Issue (4): 392-400.doi: 10.7518/gjkq.2024078

• Periodontitis • Previous Articles    

Therapeutic effect of cannabidiol combined with minocycline on periodontitis

Meiyao Qi(),Xingying Qi,Xinyi Zhou,Zhen Tan,Quan Yuan()   

  1. State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases & Dept. of Implantology, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China
  • Received:2023-03-25 Revised:2023-06-29 Online:2024-07-01 Published:2024-06-24
  • Contact: Quan Yuan E-mail:727198073@qq.com;yuanquan@scu.edu.cn
  • Supported by:
    West China Hospital of Stomatology Sichuan University Interdisciplinary Innovation Project(RD-03-202010);Sichuan Province International Science and Technology Cooperation Project(2021YFH0015)

RichHTML

24

PDF (PC)

681

Abstract:

Objective The therapeutic effect of cannabidiol combined with minocycline on experimental periodontitis in mice was studied in vitro and in vivo. Methods The mouse periodontitis model was established by thread ligation. The oral area was treated with cannabidiol, minocycline, and both. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to detect the changes in inflammatory factors in peripheral blood of mice with periodontitis. Micro CT, western blot (WB), and hematoxylin-eosin (HE) staining were used to analyze the improvement in local inflammation. Porphyromonas gingivalis (P. gingivalis) bacteriostatic assay was used to detect the antibacterial properties of the combined drugs in vitro. Inflammation of macrophages and gingival fibroblasts was induced in vitro, and mRNA expression related to inflammation was detected by qRT-PCR. The effect of drugs on cell migration was explored by wound-healing assay, and the effect of drugs on collagen production was explored by enzyme-linked immunosorbent assay. Results After combined administration of cannabidiol and minocycline, the systemic inflammation index of mice decreased, the local attachment loss was alleviated, the tissue inflammation level was reduced, and the destruction of periodontal soft and hard tissues improved compared with single administration. The results of the antibacterial experiment in vitro showed that the combined drugs had good antibacterial properties. In vitro cell experiments proved that the combination of drugs reduced the expression levels of various inflammatory factors in macrophages, promoted the proliferation and migration of human gingival fibroblasts in inflammatory states, and improved the collagen formation function. Conclusion Compared with the single medication method, the local application of cannabidiol combined with minocycline has a significant effect on experimental periodontitis in mice.

Key words: periodontitis, cannabidiol, minocycline, antibiotic

CLC Number: 

  • R781.4+2

TrendMD: 

Fig 1

Micro CT 3D reconstruction and analysis of mouse jaw after administration"

Fig 2

Changes in local and systemic inflammation levels in periodontal mice after drug administration"

Fig 3

In vitro bacteriostatic effect of CBD+MINO"

Fig 4

CBD+MINO treatment affected the secretion of inflammatory cytokines in RAW264.7 cells"

Fig 5

HGF cell wound-healing test results"

Fig 6

Combination of drugs to enhance collagen production in HGF cells under inflammation"

1 Kwon T, Lamster IB, Levin L. Current concepts in the management of periodontitis[J]. Int Dent J, 2021, 71(6): 462-476.
2 Fischer RG, Lira Junior R, Retamal-Valdes B, et al. Periodontal disease and its impact on general health in Latin America. Section V: treatment of periodontitis[J]. Braz Oral Res, 2020, 34(supp1 1): e026.
3 Simpson TC, Clarkson JE, Worthington HV, et al. Treatment of periodontitis for glycaemic control in people with diabetes mellitus[J]. Cochrane Database Syst Rev, 2022, 4(4): CD004714.
4 Lin HB, Chen HS, Zhao XT, et al. Advances of exosomes in periodontitis treatment[J]. J Transl Med, 2022, 20(1): 279.
5 GBD Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2018, 392(10159): 1789-1858.
6 台保军. 中国居民口腔健康状况及防控策略：第四次全国口腔健康流行病学调查结果解读[C]//第十三次全国老年口腔医学学术年会论文汇编. 武汉, 2018: 16-17.
Tai BJ. Oral health status of Chinese residents and prevention and control strategies: interpretation of the results of the fourth national oral health epide-miological survey[C]//The 13th National Annual Conference of Geriatric Stomatology. Wuhan, 2018: 16-17.
7 Hajishengallis G. Periodontitis: from microbial immune subversion to systemic inflammation[J]. Nat Rev Immunol, 2015, 15(1): 30-44.
8 Hajishengallis G, Chavakis T. Local and systemic mechanisms linking periodontal disease and inflammatory comorbidities[J]. Nat Rev Immunol, 2021, 21(7): 426-440.
9 Genco RJ, Sanz M. Clinical and public health implications of periodontal and systemic diseases: an overview[J]. Periodontol 2000, 2020, 83(1): 7-13.
10 Pisanti S, Malfitano AM, Ciaglia E, et al. Cannabi-diol: state of the art and new challenges for therapeutic applications[J]. Pharmacol Ther, 2017, 175: 133-150.
11 Oláh A, Tóth BI, Borbíró I, et al. Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes[J]. J Clin Invest, 2014, 124(9): 3713-3724.
12 Wroński A, Jarocka-Karpowicz I, Stasiewicz A, et al. Phytocannabinoids in the pharmacotherapy of psoriasis[J]. Molecules, 2023, 28(3): 1192.
13 Ramer R, Hinz B. Cannabinoid compounds as a pharmacotherapeutic option for the treatment of non-cancer skin diseases[J]. Cells, 2022, 11(24): 4102.
14 Casares L, García V, Garrido-Rodríguez M, et al. Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1[J]. Redox Biol, 2020, 28: 101321.
15 Malfait AM, Gallily R, Sumariwalla PF, et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis[J]. Proc Natl Acad Sci U S A, 2000, 97(17): 9561-9566.
16 Qi X, Lin W, Wu Y, et al. CBD promotes oral ulcer healing via inhibiting CMPK2-mediated inflammasome[J]. J Dent Res, 2022, 101(2): 206-215.
17 Singh S, Khanna D, Kalra S. Minocycline and doxycycline: more than antibiotics[J]. Curr Mol Pharmacol, 2021, 14(6): 1046-1065.
18 Asadi A, Abdi M, Kouhsari E, et al. Minocycline, focus on mechanisms of resistance, antibacterial activity, and clinical effectiveness: back to the future[J]. J Glob Antimicrob Resist, 2020, 22: 161-174.
19 Afshari AR, Mollazadeh H, Sahebkar A. Minocycline in treating glioblastoma multiforme: far beyond a conventional antibiotic[J]. J Oncol, 2020, 2020: 8659802.
20 Derfuss T, Mehling M, Papadopoulou A, et al. Advances in oral immunomodulating therapies in relapsing multiple sclerosis[J]. Lancet Neurol, 2020, 19(4): 336-347.
21 Dogaru IA, Puiu MG, Manea M, et al. Current perspectives on pharmacological and non-pharmacolo-gical interventions for the inflammatory mechanism of unipolar depression[J]. Brain Sci, 2022, 12(10): 1403.
22 Morris G, Walker AJ, Berk M, et al. Cell death pathways: a novel therapeutic approach for neuroscientists[J]. Mol Neurobiol, 2018, 55(7): 5767-5786.
23 Shankar C, Nabarro LEB, Anandan S, et al. Minocycline and tigecycline: what is their role in the treatment of carbapenem-resistant gram-negative orga-nisms[J]. Microb Drug Resist, 2017, 23(4): 437-446.
24 Franco V, Gershkovich P, Perucca E, et al. The interplay between liver first-pass effect and lymphatic absorption of cannabidiol and its implications for cannabidiol oral formulations[J]. Clin Pharmacokinet, 2020, 59(12): 1493-1500.
25 Kim EK, Jang SH, Choi YH, et al. Effect of an oral hygienic care program for stroke patients in the intensive care unit[J]. Yonsei Med J, 2014, 55(1): 240-246.
26 de Molon RS, Mascarenhas VI, de Avila ED, et al. Long-term evaluation of oral gavage with periodontopathogens or ligature induction of experimental periodontal disease in mice[J]. Clin Oral Investig, 2016, 20(6): 1203-1216.
27 Polak D, Wilensky A, Shapira L, et al. Mouse model of experimental periodontitis induced by Porphyromonas gingivalis/Fusobacterium nucleatum infection: bone loss and host response[J]. J Clin Perio-dontol, 2009, 36(5): 406-410.
28 Chen WP, Chang SH, Tang CY, et al. Composition analysis and feature selection of the oral microbiota associated with periodontal disease[J]. Biomed Res Int, 2018, 2018: 3130607.
29 Teles F, Collman RG, Mominkhan D, et al. Viruses, periodontitis, and comorbidities[J]. Periodontol 2000, 2022, 89(1): 190-206.
30 Xu WZ, Zhou W, Wang HZ, et al. Roles of Porphyromonas gingivalis and its virulence factors in pe-riodontitis[J]. Adv Protein Chem Struct Biol, 2020, 120: 45-84.
31 Herrera D, Sanz M, Kebschull M, et al. Treatment of stage Ⅳ periodontitis: the EFP S3 level clinical practice guideline[J]. J Clin Periodontol, 2022, 49(): 4-71.
32 West N, Chapple I, Claydon N, et al. BSP implementation of European S3-level evidence-based treatment guidelines for stage Ⅰ-Ⅲ periodontitis in UK clinical practice[J]. J Dent, 2021, 106: 103562.
33 Oh TJ, Yu SH. Evidence-based clinical practice guideline for treatment of stage IIII periodontitis[J]. J Evid Based Dent Pract, 2021, 21(4): 101638.
34 Stahl V, Vasudevan K. Comparison of efficacy of cannabinoids versus commercial oral care products in reducing bacterial content from dental plaque: a preliminary observation[J]. Cureus, 2020, 12(1): e6809.
35 Fatima T, Khurshid Z, Rehman A, et al. Gingival crevicular fluid (GCF): a diagnostic tool for the detection of periodontal health and diseases[J]. Molecules, 2021, 26(5): 1208.
36 Surlin P, Gheorghe DN, Popescu DM, et al. Interleukin-1α and-1β assessment in the gingival crevicular fluid of periodontal patients with chronic hepatitis C[J]. Exp Ther Med, 2020, 20(3): 2381-2386.
37 Preshaw PM, Taylor JJ, Jaedicke KM, et al. Treatment of periodontitis reduces systemic inflammation in type 2 diabetes[J]. J Clin Periodontol, 2020, 47(6): 737-746.
38 Li C, Yu R, Ding YM. Association between Porphyromonas Gingivalis and systemic diseases: focus on T cells-mediated adaptive immunity[J]. Front Cell Infect Microbiol, 2022, 12: 1026457.
39 Yang RQ, Guo SJ, Xiao SM, et al. Enhanced wound healing and osteogenic potential of photodynamic therapy on human gingival fibroblasts[J]. Photodiagnosis Photodyn Ther, 2020, 32: 101967.
40 Amberg R, Elad A, Rothamel D, et al. Design of a migration assay for human gingival fibroblasts on biodegradable magnesium surfaces[J]. Acta Biomater, 2018, 79: 158-167.
[1] Zaimu Yang,Pei Cao,Zhenhua Liu,Qingxian Luan. Correlation study of plasma cell-free extra-mitochondrial mitochondria DNA and periodontitis clinical parameters [J]. Int J Stomatol, 2024, 51(3): 288-295.
[2] Yuhong Ma,Lei Zhao. Process and progress in the clinical research of minimally invasive non-operative periodontal therapy technology [J]. Int J Stomatol, 2024, 51(2): 227-232.
[3] Fu Yu, He Wei, Huang Lan. Ferroptosis and its implication in oral diseases [J]. Int J Stomatol, 2024, 51(1): 36-44.
[4] Luo Xiaojie,Wang Dexu,Chen Xiaotao. Relationship between periodontitis and ferroptosis based on bioinformatics analysis [J]. Int J Stomatol, 2023, 50(6): 661-668.
[5] Huang Yuanhong,Peng Xian,Zhou Xuedong.. Progress in research into the effect of Rhizoma Drynariae on the treatment of bone-related diseases in the oral cavity [J]. Int J Stomatol, 2023, 50(6): 679-685.
[6] Hu Jia,Wang Xiuqing,Lu Guoying,Huang Xiaojing.. Regenerative endodontic procedures for permanent tooth with immature apices in adult patients [J]. Int J Stomatol, 2023, 50(6): 686-695.
[7] Wang Renyi,Zhao Chengzhi,Pan Jian.. Research progress on the effects of prophylactic antibiotics on postoperative complications during the perioperative period of tooth extraction [J]. Int J Stomatol, 2023, 50(5): 558-565.
[8] Gong Meiling,Cheng Xingqun,Wu Hongkun.. Research progress on the correlation between Parkinson’s disease and periodontitis [J]. Int J Stomatol, 2023, 50(5): 587-593.
[9] Xu Zhibo,Meng Xiuping.. Research progress on mechanism of Enterococcus faecalis escaping host immune defense [J]. Int J Stomatol, 2023, 50(5): 613-617.
[10] Sun Jia,Han Ye,Hou Jianxia. Research progress on the role of interleukin-6-hepcidin signal axis in regulating the pathogenesis of periodontitis-associated anemia [J]. Int J Stomatol, 2023, 50(3): 329-334.
[11] Liang Zhiying,Zhao Yuanxi,Zhu Jiani,Su Qin.. Retrospective analysis of clinical data of 288 cases of endodontic microsurgery on anterior teeth [J]. Int J Stomatol, 2023, 50(2): 166-171.
[12] Liu Tiqian,Liang Xing,Liu Weiqing,Li Xiaohong,Zhu Rui.. Research progress on the role and mechanism of occlusal trauma in the development of periodontitis [J]. Int J Stomatol, 2023, 50(1): 19-24.
[13] Li Qiong,Yu Weixian. Research progress on resveratrol for the treatment of periodontitis and its bioavailability [J]. Int J Stomatol, 2023, 50(1): 25-31.
[14] Huang Weikun,Xu Qiuyan,Zhou Ting.. Role of baicalin and mechanisms through which baicalin attenuates oxidative stress injury induced by lipopolysaccharide on macrophages [J]. Int J Stomatol, 2022, 49(5): 521-528.
[15] Zhou Jianpeng,Xie Xudong,Zhao Lei,Wang Jun.. Research progress on the roles and mechanisms of T-helper 17 cells and interleukin-17 in periodontitis [J]. Int J Stomatol, 2022, 49(5): 586-592.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!